Over 12 months, Kalaris Therapeutics, Inc. saw more buying than selling from its insiders — purchases of about $6.2 million against sales of $13,000.
Samsara Opportunity Fund, L.P. (Director) made the biggest buy, worth around $5 million.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. 57 investment managers listed KLRS in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Samsara BioCapital, L.P. | Director | Buy | 244,300 | $4.83 | $1.2M | SEC |
| Mar 23, 2026 | Hagen Brett R | Executive Officer | Sell | 1,915 | $6.72 | $13K | SEC |
| Feb 17, 2026 | Samsara Opportunity Fund, L.P. | Director | Buy | 479,847 | $10.42 | $5.0M | SEC |
| Mar 27, 2025 | Hagen Brett R | Executive Officer | Sell | 907 | $8.97 | $8K | SEC |
In the last 12 months Kalaris Therapeutics, Inc. insiders made open-market purchases worth about $6.2 million and sales worth about $13,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in KLRS was filed on 2026-05-22.
57 investment managers reported holding KLRS in SEC Form 13F filings for Q2 2026.
No congressional trades in KLRS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).